Comparative Inhibitory Effects of Cilostazol and Ticlopidine on Subacute Stent Thrombosis and Platelet Function in Acute Myocardial Infarction Patients With Percutaneous Coronary Intervention

Kawata, Masahito; Kuramoto, Emi; Kataoka, Toshiya; Saito, Atsushi; Adachi, Kazumasa; Matsuura, Akira; Sakamoto, Susumu

doi:10.1536/ihj.46.13

Cited by 10 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cilostazol has been shown to inhibit the aggregation response to various agonists in blood from healthy individuals, CAD and PAD patients. 18,23,24 Similar effects have also been described with aspirin. 23,25 The effect of combination treatment with aspirin and cilostazol has been investigated in patients with IHD by Tanigawa et al Aggregation studies demonstrated that combination treatment significantly inhibited AAinduced aggregation.…”

Section: Discussionsupporting

confidence: 60%

Combined Aspirin and Cilostazol Treatment is Associated with Reduced Platelet Aggregation and Prevention of Exercise-Induced Platelet Activation

Cleanthis

Bhattacharya

Smout

et al. 2009

European Journal of Vascular and Endovascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 60%

Combined Aspirin and Cilostazol Treatment is Associated with Reduced Platelet Aggregation and Prevention of Exercise-Induced Platelet Activation

Cleanthis

Bhattacharya

Smout

et al. 2009

European Journal of Vascular and Endovascular Surgery

View full text Add to dashboard Cite

show abstract

“…27) However, we did not perform an IVUS study. In addition, we do not know whether our observations for the ACE inhibitor group may have been influenced by a relatively weaker antiplatelet coagulation effect of cilostazol compared to ticlopidine 28) and a possible resultant difference in the effect of platelet-derived growth factor. Finally, we did not investigate the histopathological mechanisms of in-stent restenosis and its modification by the therapies.…”

Section: Effect Of Basal Antiplatelet Treatmentmentioning

confidence: 89%

Effects of Angiotensin-Converting Enzyme Inhibitors or an Angiotensin Receptor Blocker in Combination With Aspirin and Cilostazol on In-stent Restenosis

et al. 2006

View full text Add to dashboard Cite

SUMMARYIt remains to be determined whether adding an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) to antiplatelet therapy has a therapeutic benefit on in-stent restenosis.After successful coronary stenting, 165 patients (167 lesions) were randomly assigned to a basal (aspirin 162 mg + cilostazol 200 mg/day), ACEI (basal treatment + quinapril 10 mg or perindopril 4 mg/day), or ARB (basal treatment + losartan 50 mg/day) treatment group. Quantitative coronary angiography was performed before, immediately following, and 6 months after stenting. Follow-up coronary angiography was completed in 126 patients (128 lesions). Restenosis rates tended to be higher (12, 26, and 12% for the basal, ACEI, and ARB groups, respectively), and target lesion revascularization rates were higher in the ACEI group than in the other groups (9, 23,* and 5%, respectively, *P < 0.05 versus basal group). Moreover, late lumen loss was higher in the ACEI group than in the basal group (0.60 ± 0.55, 0.98 ± 0.61* and 0.73 ± 0.64 mm in the basal, ACEI, and ARB groups, respectively).The combinations of an ACEI or ARB with aspirin and cilostazol are ineffective for the prevention of in-stent restenosis, and an ACEI may even promote intimal proliferation after stent implantation. (Int Heart J 2006; 47: 173-184)

show abstract

“…However, there have been few studies of the impact of dipyridamole treatment on long-term outcome in patients with LV dysfunction. 19,20 Though our study is limited by the fact that it was retrospective, involving an observational cohort, propensity analysis was used to adjust for the different backgrounds. 21 Thus, our data demon- strated that dipyridamole therapy was effective in terms of long-term clinical outcomes in Japanese patients in whom complete revascularization was achieved.…”

Section: Discussionmentioning

confidence: 99%

Dipyridamole Therapy Improves Long-Term Survival After Complete Revascularization in Patients With Impaired Cardiac Function A Propensity Analysis

Ikeda

Kasai

Kajimoto

et al. 2008

Circ J

View full text Add to dashboard Cite

ipyridamole is an antiplatelet agent that inhibits the cellular reuptake of adenosine, leading to increased extracellular concentrations of adenosine. 1 Adenosine has cardioprotective actions: it activates adenosine receptors, resulting in attenuation of catecholamine release, -adrenoceptor-mediated myocardial hypercontraction, and Ca 2+ overload via A1 receptors, and increases coronary blood flow and inhibits platelet and leukocyte activation via A2 receptors. A meta-analysis of 13 randomized, placebocontrolled trials published between 1960 and 1992 demonstrated the beneficial effect of dipyridamole with respect to the prevention of angina pectoris, particularly with a longer duration of treatment. 2 In experimental studies, absolute coronary flow is increased when collateral circulation is not present. 3 However, dipyridamole induced myocardial ischemia that depended on collateral circulation in some patients with coronary artery disease (CAD), because dipyridamole decreased flow to collateral-dependent vascular beds through "coronary steal". [4][5][6] Coronary steal is conventionally defined as an absolute decrease in perfusion, compared with resting flow, to collateralized myocardium following coronary vasodilation. Therefore, dipyridamole and adenosine are used in diagnostic examinations for detecting myocardial ischemia, 7,8 rather than as treatment for CAD, 9 because of the coronary steal phenomenon. In recent studies, elevation of serum adenosine by administration of dipyridamole improved cardiac function in patients with heart failure; 10,11 however, there are few data regarding the long-term effects of dipyridamole on mortality and cardiovascular events in Japanese patients. The aim of this study was to assess whether the use of dipyridamole after complete revascularization affects long-term mortality in patients with impaired left ventricular (LV) systolic function. Methods SubjectsData from consecutive patients who had undergone surgical and/or percutaneous coronary revascularization at Juntendo University Hospital between January 1984 and December 1992 were analyzed. Patients were enrolled who met the inclusion criteria: (1) achieved complete revascularization, defined as no un-bypassed major vessels with a ≥50% stenosis, 12,13 and (2) had impaired LV systolic function, defined as a LV ejection fraction (LVEF) <50% on echocardiography at the time when complete revascularization was achieved. Patients who had other known life-threatening diseases at baseline and patients who had associated complex cardiac procedures, such as valve replacement or aneurysm repair at the time of surgical revascularization, were excluded.

show abstract

Comparative Inhibitory Effects of Cilostazol and Ticlopidine on Subacute Stent Thrombosis and Platelet Function in Acute Myocardial Infarction Patients With Percutaneous Coronary Intervention

Cited by 10 publications

References 21 publications

Combined Aspirin and Cilostazol Treatment is Associated with Reduced Platelet Aggregation and Prevention of Exercise-Induced Platelet Activation

Combined Aspirin and Cilostazol Treatment is Associated with Reduced Platelet Aggregation and Prevention of Exercise-Induced Platelet Activation

Effects of Angiotensin-Converting Enzyme Inhibitors or an Angiotensin Receptor Blocker in Combination With Aspirin and Cilostazol on In-stent Restenosis

Dipyridamole Therapy Improves Long-Term Survival After Complete Revascularization in Patients With Impaired Cardiac Function A Propensity Analysis

Contact Info

Product

Resources

About